In Vitro Activity of Fenticonazole against Candida and Bacterial Vaginitis Isolates Determined by Mono- or Dual-Species Testing Assays.

We determined the in vitro activity of fenticonazole against 318 vaginitis isolates of Candida and bacterial species, and selected 28 isolates for time-kill curve studies. At concentrations equal to 4× MIC, fenticonazole reached the 99.9% killing endpoint by ∼10 h for S. aureus , S. agalactiae , and E. coli ; ∼17 h for both C. albicans and C. parapsilosis ; at concentrations equal to 8× MIC, by ∼19 and ∼20 h for C. glabrata and C. tropicalis , respectively. At concentrations equal to 2× MIC, fenticonazole required ∼20 h to reach the above endpoint against C. albicans in mixed culture with S. aureus , S. agalactiae , or E. coli , compared to ∼17 h against C. albicans in pure culture. Supra-MIC concentrations are achievable in topically treated patients' vaginal surfaces.